Coherus Oncology (CHRS) Price to FCF (2014 - 2026)

Coherus Oncology has disclosed Price to FCF across 13 years of filings, most recently posting 3.48 for Q2 2026.

• In Q2 2026, Price to FCF fell 1893.03% year-over-year to 3.48; the TTM figure through Jun 2026 stood at 1.11 (down 588.81% YoY), while the FY2025 annual figure was 0.52, down 32.6% from the prior year.
• Price to FCF came in at 3.48 for Q2 2026 at Coherus Oncology, up from 4.5 in the prior quarter.
• In the past five years, Price to FCF ranged from a high of 5.58 in Q4 2024 to a low of 28.81 in Q4 2023.
• Average Price to FCF over 5 years is 6.87, with a median of 5.31 recorded in 2025.
• Year-over-year, Price to FCF soared 124.06% in 2024 and plunged 1893.03% in 2026.
• Over 5 years, Price to FCF stood at 6.24 in 2022, then plunged by 361.49% to 28.81 in 2023, then soared by 119.36% to 5.58 in 2024, then plunged by 209.81% to 6.12 in 2025, then soared by 43.13% to 3.48 in 2026.
• Per Business Quant data, the three most recent Price to FCF figures were 3.48 in Q2 2026, 4.5 in Q1 2026, and 6.12 in Q4 2025.